Journal
ACS CHEMICAL NEUROSCIENCE
Volume 2, Issue 6, Pages 279-280Publisher
AMER CHEMICAL SOC
DOI: 10.1021/cn2000469
Keywords
Alzheimer's disease; gamma-secretase; clinical trials; ELND006; semagacestat
Ask authors/readers for more resources
ELND006 is a novel gamma-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule gamma-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroomlilly.com/releasedetal.cfm?releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
